Cancer Management and Research (Dec 2022)
Health-Related Quality of Life of Patients with Metastatic Pancreatic Cancer: A Systematic Literature Review
Abstract
Hyun Kyoo Yoo,1 Nikunj Patel,2 Seongjung Joo,3 Suvina Amin,2 Rowena Hughes,4 Rajinder Chawla5 1Health Economics & Payer Evidence AstraZeneca, Cambridge, UK; 2Oncology Business Unit, AstraZeneca, Gaithersburg, MD, USA; 3MRL, Center for Observational & Real-World Evidence (CORE), Oncology, Merck Sharp & Dohme LLC, a Subsidiary of Merck & Co., Inc, Rahway, NJ, USA; 4AccuScript Consultancy, Reading, Berkshire, UK; 5AccuScript Consultancy, Ludhiana, Punjab, IndiaCorrespondence: Hyun Kyoo Yoo, Global Value, Access and Pricing, Alexion, AstraZeneca Rare Disease, City House, 130 Hills Road, Cambridge, CB2 1RE, UK, Email [email protected]: Metastatic pancreatic cancer (mPaC) has a poor prognosis and available treatments provide only moderate improvements in survival. Preserving or improving health-related quality of life (HRQoL) is therefore an important treatment outcome for patients with mPaC. This systematic review identified HRQoL data in patients with mPaC before and after treatment, compared these with data from the general population, and reported the effects of different mPaC treatments on HRQoL.Methods: Searches were performed in Embase, PubMed, and the Cochrane Library from January 2008 to May 2021, and the articles identified were screened for HRQoL data in patients with mPaC. Abstracts from relevant congresses were also manually searched. Publications included were randomized controlled trials and observational studies written in English that reported HRQoL data for adult patients with non-resectable mPaC who were on or off treatment.Results: Thirty relevant publications were identified and HRQoL scores were collected. Overall, baseline mean scores from the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), 5-dimension EuroQol questionnaire (EQ-5D), and Functional Assessment of Cancer Therapy-General (FACT-G) for newly diagnosed and previously treated patients with mPaC were worse than those of the general population. Baseline scores were generally better for previously treated patients than for newly diagnosed patients, indicating that mPaC treatments preserve or improve HRQoL. Identified publications also reported changes in HRQoL following first- or subsequent-line chemotherapy. When reported, 10 studies found improvements in overall HRQoL compared with baseline scores, four reported no changes in overall HRQoL after treatment, and six found deteriorations in overall HRQoL.Conclusion: Patients with mPaC had worse HRQoL than the general population. Available anti-cancer therapies can improve or preserve HRQoL.Keywords: health-related quality of life, metastatic pancreatic cancer, symptoms
